Cara Therapeutics Inc (OQ:CARA)

Sector:  Healthcare Industry:  Pharmaceuticals
 
See Regulatory Filings on SEC
Company Contact
Address: 400 Atlantic Street, Suite 500
STAMFORD CT 06901
Tel: N/A
Website: https://www.caratherapeutics.com
IR: See website
<
Key People
Christopher A. Posner
President, Chief Executive Officer, Director
Ryan D. Maynard
Chief Financial Officer
Frederique Menzaghi
Senior Vice President - Research and Development, Chief Scientific Officer
Scott M. Terrillion
Chief Compliance Officer, General Counsel, Secretary
Joana Goncalves
Chief Medical Officer
 
Business Overview
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back. It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis. The IV formulation is out-licensed worldwide.
Financial Overview
For the fiscal year ended 31 December 2023, Cara Therapeutics Inc revenues decreased 50% to $21M. Net loss increased 39% to $118.5M. Revenues reflect License and milestone fees decrease of 94% to $910K, Commercial supply revenue decrease of 43% to $5.8M, Collaborative revenue decrease of 22% to $12.9M. Higher net loss reflects Research and development - Balancing increase of 21% to $100.3M (expense).
Employees: 55 as of Mar 1, 2024
Reporting Currency: U.S. Dollars
Enterprise value: N/A
Annual revenue (TTM): $20.97M as of Dec 31, 2023
EBITDA (TTM): -$121.24M as of Dec 31, 2023
Net annual income (TTM): -$118.51M as of Dec 31, 2023
Free cash flow (TTM): -$94.45M as of Dec 31, 2023
Net Debt Last Fiscal Year: N/A
Shares outstanding: 54,656,413 as of Mar 1, 2024
TTM: Trailing Twelve Months
EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.